Pemetrexed disodium heptahydrate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100710

CAS#: 357166-29-1 (sodium hydrate)

Description: Pemtrexed disodium is the disodium salt of a synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS) which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.


Price and Availability

Size
Price

2g
USD 150
50g
USD 1650
Size
Price

10g
USD 550
100g
USD 2850
Size
Price

20g
USD 950
500g
USD 6650

Pemetrexed disodium heptahydrate, purity > 98%, is in stock. The same day shipping out after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 100710
Name: Pemetrexed disodium heptahydrate
CAS#: 357166-29-1 (sodium hydrate)
Chemical Formula: C20H33N5Na2O13
Exact Mass:
Molecular Weight: 597.49
Elemental Analysis: C, 40.21; H, 5.57; N, 11.72; Na, 7.70; O, 34.81


Related CAS #: 357166-29-1 (sodium hydrate)   150399-23-8 (disodium)   137281-23-3 (free acid)   357166-30-4 (sodium 2.5 hydrate)    

Synonym: LY231514; LY-231514; LY 231514; Pemetrexed, US brand name: ALIMTA. Abbreviation: MTA.

IUPAC/Chemical Name: sodium (S)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioate heptahydrate.

InChi Key: QJVSMHJWAOSBMD-MYXYZBIASA-L

InChi Code: InChI=1S/C20H21N5O6.2Na.7H2O/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27;;;;;;;;;/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29);;;7*1H2/q;2*+1;;;;;;;/p-2/t13-;;;;;;;;;/m0........./s1

SMILES Code: O=C([O-])[C@@H](NC(C1=CC=C(CCC2=CNC(NC(N)=N3)=C2C3=O)C=C1)=O)CCC([O-])=O.[H]O[H].[H]O[H].[H]O[H].[H]O[H].[H]O[H].[H]O[H].[H]O[H].[Na+].[Na+]


Technical Data

Appearance:
white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Very poorly soluble in DMSO; soluble in water at 100 mg/mL; very poorly soluble in ethanol.

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO or water.

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Related CAS#
CAS#357166-29-1 (Pemetrexed disodium heptahydrate);
CAS#150399-23-8 (Pemetrexed Disodium)
CAS#137281-23-3 (Pemetrexed)

Pemetrexed (fre acid)
Chemical Formula: C20H21N5O6
Exact Mass: 427.1492
Molecular Weight: 427.4170
Elemental Analysis: C, 56.20; H, 4.95; N, 16.39; O, 22.46


References

1: Liu Y, Yin TJ, Zhou R, Zhou S, Fan L, Zhang RG. Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis. Cancer Chemother Pharmacol. 2013 Nov;72(5):1125-32. doi: 10.1007/s00280-013-2299-2. Epub 2013 Sep 26. Review. PubMed PMID: 24067998.

2: Boons CC, VAN Tulder MW, Burgers JA, Beckeringh JJ, Wagner C, Hugtenburg JG. The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review. Anticancer Res. 2013 Sep;33(9):3553-61. Review. PubMed PMID: 24023280.

3: Genova C, Rijavec E, Truini A, Coco S, Sini C, Barletta G, Dal Bello MG, Alama A, Savarino G, Pronzato P, Boccardo F, Grossi F. Pemetrexed for the treatment of non-small cell lung cancer. Expert Opin Pharmacother. 2013 Aug;14(11):1545-58. doi: 10.1517/14656566.2013.802774. Epub 2013 May 17. Review. PubMed PMID: 23683110.

4: Tomasini P, Greillier L, Khobta N, Barlesi F. The place of pemetrexed in the management of non-small-cell lung cancer patients. Expert Rev Anticancer Ther. 2013 Mar;13(3):257-66. doi: 10.1586/era.12.171. Review. PubMed PMID: 23477511.

5: Argiris A, Pennella E, Koustenis A, Hossain AM, Obasaju CK. Pemetrexed in head and neck cancer: a systematic review. Oral Oncol. 2013 Jun;49(6):492-501. doi: 10.1016/j.oraloncology.2013.01.007. Epub 2013 Mar 7. Review. PubMed PMID: 23466170.

6: Gilani SN, Gridley R, Searle G, Jegannathen A. Malignant peritoneal mesothelioma (MPM) who responded to rechallenge with cisplatin and pemetrexed with current literature review. BMJ Case Rep. 2013 Jan 3;2013. pii: bcr2012007786. doi: 10.1136/bcr-2012-007786. Review. PubMed PMID: 23291819.

7: Qi WX, Tang LN, He AN, Shen Z, Lin F, Yao Y. Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison. Curr Med Res Opin. 2012 Apr;28(4):643-50. doi: 10.1185/03007995.2012.675880. Epub 2012 Mar 29. Review. PubMed PMID: 22414178.

8: Morotti M, Valenzano Menada M, Venturini PL, Mammoliti S, Ferrero S. Pemetrexed disodium in ovarian cancer treatment. Expert Opin Investig Drugs. 2012 Apr;21(4):437-49. doi: 10.1517/13543784.2012.661714. Epub 2012 Feb 13. Review. PubMed PMID: 22324304.

9: Qi WX, Tang LN, He AN, Shen Z, Yao Y. Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2012 May;138(5):745-51. doi: 10.1007/s00432-012-1155-9. Epub 2012 Jan 19. Review. PubMed PMID: 22258853.

10: Sørensen JB. Pharmacokinetic evaluation of pemetrexed. Expert Opin Drug Metab Toxicol. 2011 Jul;7(7):919-28. doi: 10.1517/17425255.2011.587411. Epub 2011 May 21. Review. PubMed PMID: 21599552.